Standout Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (2020)
Immediate Impact
3 by Nobel laureates 3 from Science/Nature 80 standout
Citing Papers
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 Standout
Works of Tibor Csőszi being referenced
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
2021 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Tibor Csőszi | 8820 | 5714 | 779 | 1883 | 81 | 10.4k | |
| Sinéad Cuffe | 8340 | 5706 | 853 | 1839 | 99 | 10.7k | |
| Reshma Rangwala | 6851 | 4324 | 676 | 1768 | 40 | 8.9k | |
| Maya Gottfried | 10411 | 7572 | 931 | 1924 | 155 | 12.9k | |
| Gregory M. Lubiniecki | 11987 | 7988 | 939 | 2782 | 55 | 13.9k | |
| Marisa Dolled‐Filhart | 7920 | 4746 | 1256 | 1898 | 69 | 11.0k | |
| Yue Shentu | 10488 | 6838 | 983 | 2446 | 34 | 12.3k | |
| Marcin Kowanetz | 9158 | 5621 | 662 | 2548 | 106 | 11.9k | |
| Michael Smylie | 7094 | 4305 | 322 | 1587 | 92 | 8.9k | |
| Jamie E. Chaft | 6776 | 6179 | 823 | 963 | 170 | 9.8k | |
| Laura Q.M. Chow | 8861 | 4544 | 1279 | 2951 | 156 | 12.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...